Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial MeningiomaSylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Clinical Cancer Research|2023Cited by 55
CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDYSylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Neuro-Oncology|2022Cited by 2
A Phase 2 Exploratory Trial Evaluating Computed Tomography–Based Midtreatment Nodal Response to Select for De-escalated Chemoradiation Therapy in the Definitive Management of p16+ Oropharyngeal CancerJoseph K. Kim, Kenneth S. Hu, Moses Tam et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 2
Data from Evaluation of the SSTR2-targeted Radiopharmaceutical <sup>177</sup>Lu-DOTATATE and SSTR2-specific <sup>68</sup>Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial MeningiomaSylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Unknown|2024Cited by 1
CTNI-41. RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMASylvia C. Kurz, Erik P. Sulman, Elçin Zan et al.|Neuro-Oncology|2025Cited by 1